Clinical trial
Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study
NCT01548014 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study
- Lead sponsor
- Samsung Medical Center
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2010
- Completion date
- January 31, 2016
- Enrollment
- 1 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease